# Arcutis Biotherapeutics Inc. (ARQT) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $23.90, market value $3.0 billion.

## Valuation
- **P/E (trailing): 108.6×**. Arcutis Biotherapeutics Inc. trades at 108.6× trailing earnings. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 18.3×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.21**. A PEG of 0.21 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 6.5×**. Each dollar of revenue is priced at 6.5×.
- **Price / book: 13.6×**. The shares trade at 13.6× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: 1.3%** (5-yr avg -33.2%). Free cash flow equals 1.3% of the market value, above its five-year average of -33.2%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 0.9%**. The inverse of the P/E: 0.9% of the price is earned each year.

## Profitability
- **Operating margin: 7.4%**. 7.4% of revenue is left after running the business.
- **Net margin: -4.3%**. The company reported a net loss over the last twelve months.
- **Return on equity: -8.5%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 10.6%**. Return on all capital, debt included, is 10.6%.
- **Return on assets: 6.6%**. Each dollar of assets produces 6.6% of profit.

## Growth
- **Revenue growth (1 yr): 91.3%** (3-yr 367.3%/yr). Revenue grew 91.3% over the last year.
- **EPS growth (1 yr): 88.8%**. Earnings per share rose 88.8%, roughly in step with revenue.

## Financial health
- **Debt to equity: 0.58**. Debt is 0.58 times equity, moderate leverage.
- **Altman Z-score: 8.79**. A Z-score of 8.79 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Arcutis Biotherapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (8 analysts). 8 analysts cover Arcutis Biotherapeutics Inc.; the consensus is strong_buy, with an average price target of $36.88 (+54% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 47.4%** (YTD -17.7%, 3-mo 12.6%). The shares are up 47.4% over twelve months including dividends.
- **From 52-week high: -24.8%** (44.2% above the low). Trading 25% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 38**. An RSI of 38 is neutral.
- **Beta (1 yr): 1.16** (volatility 56%). Beta of 1.16 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ARQT · Page: https://foliofundamentals.com/stocks/arqt

Not investment advice.